Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Shares Issued (2021 - 2024)

Immuneering (IMRX) has 4 years of Shares Issued data on record, last reported at $4.2 million in Q4 2024.

  • For Q4 2024, Shares Issued rose 53505.62% year-over-year to $4.2 million; the TTM value through Dec 2024 reached $4.2 million, up 844.16%, while the annual FY2024 figure was $4.2 million, 844.16% up from the prior year.
  • Shares Issued reached $4.2 million in Q4 2024 per IMRX's latest filing, up from -$247465.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $120.0 million in Q4 2021 and bottomed at -$27.8 million in Q3 2023.
  • Average Shares Issued over 4 years is $10.3 million, with a median of $110447.5 recorded in 2022.
  • The widest YoY moves for Shares Issued: up 100535.6% in 2023, down 12468.41% in 2023.
  • A 4-year view of Shares Issued shows it stood at $120.0 million in 2021, then plummeted by 100.18% to -$220895.0 in 2022, then surged by 103.55% to $7835.0 in 2023, then surged by 53505.62% to $4.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $4.2 million in Q4 2024, -$247465.0 in Q3 2024, and $247465.0 in Q2 2024.